Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-KRd Induction, Tandem ASCT, and Maintenance in High-Risk NDMM
NCT03606577Phase 2Active, not recruiting
- Sponsor
- CHU de Nantes
- Start
- Jul 2019
- Primary completion
- Feb 2022
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab and carfilzomib in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: Percentage of patients receiving the second Autologous Stem Cell Transplant at 15 months. Started Jul 2019; status: active, not recruiting.
02
Drugs
daratumumabcarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03606577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606577.